Company Filing History:

11 out of 587

King Abdulaziz University

patents

1 out of 402

Virginia Commonwealth University

patents

where one patent can have more than one assignee

Years Active: 2020-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11890380 - Buccal formulation of avanafil with enhanced bioavailability and prolonged duration (2024-02-06),

2. 11648205 - Buccal formulation of avanafil with enhanced bioavailability and prolonged duration (2023-05-16),

3. 11298321 - Methods for treating metabolic disorder (2022-04-12),

4. 11253481 - Self-nanoemulsifying 3D-printed tablet composition and method of use thereof (2022-02-22),

5. 11185513 - Transfersome-containing transdermal film formulations and methods of use (2021-11-30),

6. 11096902 - Transdermal film formulations and methods of use (2021-08-24),

7. 10813882 - In situ gelling formulation for reduced initial drug burst (2020-10-27),

8. 10799455 - Micellles containing alpha lipoic acid as a transdermal drug delivery system (2020-10-13),

9. 10744137 - Liquisolid tablet containing combined dose of tadalafil and dapoxetine (2020-08-18),

10. 10736843 - In situ gelling composition containing tocopherol-loaded micelles as an intranasal drug delivery system (2020-08-11),

11. 10653634 - Polymeric nanoparticulate formulation to enhance the oral bioavailability of dapoxetine (2020-05-19),

Title: Innovations of Khalid Mohamed El-Say: A Pioneer in Buccal Formulations

Introduction

Khalid Mohamed El-Say is a distinguished inventor based in Jeddah, Saudi Arabia. With a remarkable portfolio of 11 patents, he has made significant strides in the field of pharmaceutical formulations, particularly focusing on enhancing the bioavailability of active compounds.

Latest Patents

One of Khalid's notable patents includes a buccal formulation of avanafil designed to improve its bioavailability and prolong its duration of action. This inventive buccal tablet incorporates polyvinylpyrrolidone K-90 as the solid dispersion polymer, along with hydroxypropyl methylcellulose as the mucoadhesive polymer, sodium deoxycholate as a mucopenetration enhancer, porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil itself. The formulation is characterized by a specific ratio of PVP K-90 to avanafil (approximately 2:1), ensuring optimal performance in treating erectile dysfunction. The methods outlined for creating this buccal tablet further advance the existing therapeutic options.

Career Highlights

Khalid Mohamed El-Say has contributed to reputable institutions like King Abdulaziz University and Virginia Commonwealth University. His tenure in these organizations has facilitated his research and the development of innovative pharmaceutical products, reflecting his commitment to advancing medical treatments.

Collaborations

Throughout his career, Khalid has collaborated with distinguished colleagues, including Tarek Abdelnapy Ahmed and Osama A A Ahmed. These partnerships have fostered a dynamic exchange of ideas and expertise, propelling innovation in their respective fields.

Conclusion

Khalid Mohamed El-Say continues to be a driving force in the development of innovative pharmaceutical formulations. His work on buccal tablets for avanafil represents just a fraction of his contributions to the field, showcasing his ability to combine science and innovation effectively. With multiple patents and a strong professional network, Khalid remains an influential figure in the world of pharmaceutical inventions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com